Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma|
- Incidence of IA feasibility failure [ Time Frame: Up to 4 months ] [ Designated as safety issue: No ]Feasibility failure is defined as a) interventional radiologist is unable to access the ophthalmic artery for the 1st chemotherapy administration for any reason; b) patient develops central retinal artery occlusion after the 1st or 2nd course that does not reopen by the time the next injection is due; or c) the patient cannot receive all three treatments because of Common Terminology Criteria for Adverse Events (CTCAE) complications grade III or IV that are considered possibly, probably or likely related treatment.
- Catheter insertion complication rate [ Time Frame: Up to 48 hours after catheter insertion procedures ] [ Designated as safety issue: No ]Defined as (1) thrombosis of the femoral artery; (2) dissection of any artery; (3) hematoma at the site of insertion of 3 centimeters or more in diameter; (4) emboli cerebral; or (5) any embolus in the lower extremity that results in vascular insufficiency.
- Histopathology of eyes enucleated for progression [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]The proportion of enucleated eyes with various characteristics, such as viable vitreous seeds, invasion into the optic nerve, ischemic atrophy involving the outer retina and choroid, and extensive choroidal and outer retinal atrophy will be calculated, as well as the 95% confidence intervals.
- Incidence of grade 3 or higher CTCAE adverse events associated with multiple doses of IA chemotherapy [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]The occurrence of each grade 3 or higher CTCAE adverse experience will be recorded in each patient-cycle. The percentage of patients with each toxicity will be tabulated per cycle according to the methodology in place for the study progress report at the time.
- Probability of ocular salvage [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Rate of metastases of retinoblastoma [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
- Vision acuity, assessed according to the Amblyopia Treatment Study Visual Acuity Testing Protocol [ Time Frame: 1 year after therapy ] [ Designated as safety issue: No ]Estimated by the average visual acuity amongst patients evaluated with a 95% confidence interval.
|Study Start Date:||April 2014|
|Estimated Primary Completion Date:||February 2017 (Final data collection date for primary outcome measure)|
Experimental: Treatment (melphalan)
Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
I. To study the feasibility of delivering melphalan directly into the ophthalmic artery in children with newly diagnosed unilateral group D retinoblastoma, who would otherwise be considered for enucleation.
I. To estimate the ocular salvage rate after treatment with intra-arterial melphalan in children with newly diagnosed unilateral retinoblastoma with group D disease.
II. To evaluate the toxicities and adverse events associated with delivering multiple doses of intra-arterial chemotherapy.
III. To evaluate vision outcomes in children treated with intra-arterial chemotherapy.
IV. To monitor the rate of the development of metastatic disease while on protocol therapy.
I. To evaluate the effects of intra-arterial therapy on the histopathology of eyes enucleated for progression.
Patients receive melphalan intra-arterially (IA) on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then periodically for 2 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02097134
|United States, California|
|Children's Hospital Los Angeles||Recruiting|
|Los Angeles, California, United States, 90027|
|Contact: Leo Mascarenhas, MD MS 323-361-4110 email@example.com|
|Principal Investigator: Leo Mascarenhas, MD MS|
|UCSF Medical Center-Parnassus||Withdrawn|
|San Francisco, California, United States, 94143|
|UCSF Medical Center-Mission Bay||Recruiting|
|San Francisco, California, United States, 94158|
|Contact: Katherine K. Matthay, MD 877-827-3222 firstname.lastname@example.org|
|Principal Investigator: Katherine K. Matthay, MD|
|United States, Connecticut|
|New Haven, Connecticut, United States, 06520|
|Contact: Nina S. Kadan-Lottick, MD MSPH 203-785-5702 Nina.Kadan-Lottick@yale.edu|
|Principal Investigator: Nina S. Kadan-Lottick, MD MSPH|
|United States, Florida|
|University of Miami Miller School of Medicine-Sylvester Cancer Center||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Julio C. Barredo, MD 866-574-5124 Sylvester@emergingmed.com|
|Principal Investigator: Julio C. Barredo, MD|
|United States, Massachusetts|
|Dana-Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Carlos Rodriguez-Galindo, MD 866-790-4500 email@example.com|
|Principal Investigator: Carlos Rodriguez-Galindo, MD|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: Susan G. Kreissman, MD 888-275-3853 firstname.lastname@example.org|
|Principal Investigator: Susan G. Kreissman, MD|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: John P. Perentesis, MD 513-636-2799 email@example.com|
|Principal Investigator: John P. Perentesis, MD|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Ann-Marie Leahey, MD 215-590-2810 firstname.lastname@example.org|
|Principal Investigator: Ann-Marie Leahey, MD|
|United States, Texas|
|Baylor College of Medicine||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Murali M. Chintagumpala, MD 713-798-1354 email@example.com|
|Principal Investigator: Murali M. Chintagumpala, MD|
|Principal Investigator:||Murali Chintagumpala, MD||Children's Oncology Group|